Nuvectis Pharma, Inc.
NASDAQ:NVCT
8.35 (USD) • At close March 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Assets: | |||||
| Current Assets: | |||||
| Cash & Cash Equivalents
| 18.533 | 19.126 | 19.993 | 5.742 | 0 |
| Short Term Investments
| 0 | 0 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 18.533 | 19.126 | 19.993 | 5.742 | 0 |
| Net Receivables
| 0 | 0 | 0 | 0 | 0 |
| Inventory
| 0 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 0.074 | 0.059 | 0.412 | 0.091 | 0 |
| Total Current Assets
| 18.607 | 19.185 | 20.405 | 5.833 | 0 |
| Non-Current Assets: | |||||
| Property, Plant & Equipment, Net
| 0 | 0 | 0 | 0 | 0 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0 | 0 | 0 | 0.824 | 0 |
| Total Non-Current Assets
| 0 | 0 | 0 | 0.824 | 0 |
| Total Assets
| 18.607 | 19.185 | 20.405 | 6.657 | 0 |
| Liabilities & Equity: | |||||
| Current Liabilities: | |||||
| Account Payables
| 2.498 | 2.771 | 2.91 | 1.058 | 0.01 |
| Short Term Debt
| 0 | 0 | 0 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 6.396 | 4.213 | 3.276 | 1.361 | 0 |
| Total Current Liabilities
| 8.894 | 6.984 | 6.186 | 2.419 | 0.01 |
| Non-Current Liabilities: | |||||
| Long Term Debt
| 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities
| 0 | 0 | 2.91 | 15.246 | 0 |
| Total Liabilities
| 8.894 | 6.984 | 6.186 | 17.665 | 0.01 |
| Equity: | |||||
| Preferred Stock
| 0 | 0 | 20.405 | 15.246 | 0 |
| Common Stock
| 0 | 0 | 14,752.403 | 0 | 0 |
| Retained Earnings
| -73.245 | -54.245 | -31.985 | -12.9 | -0.01 |
| Accumulated Other Comprehensive Income/Loss
| 0 | 0 | -14,752.403 | 0 | 0 |
| Other Total Stockholders Equity
| 82.958 | 66.446 | 46.204 | 1.892 | 0 |
| Total Shareholders Equity
| 9.713 | 12.201 | 14.219 | -11.008 | -0.01 |
| Total Equity
| 9.713 | 12.201 | 14.219 | -11.008 | -0.01 |
| Total Liabilities & Shareholders Equity
| 18.607 | 19.185 | 20.405 | 6.657 | 0 |